Immunic, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Immunic is a clinical-stage biotechnology company developing oral therapies for inflammatory and autoimmune diseases. It has no approved products and generated no product revenue.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / prior period |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $18.7 million | $23.0 million |
| General and administrative expense | $5.1 million | $4.3 million |
| Total operating expenses | $23.9 million | $27.3 million |
| Net loss | $29.6 million | $25.3 million |
| Net loss per share, basic and diluted | $0.30 | $0.58 |
| Net cash used in operating activities | $24.0 million | $19.5 million |
| Cash and cash equivalents, March 31 | $97.3 million | $92.8 million at March 31, 2023 |
Operating margins are not meaningful for this pre-commercial company. The net loss increased by $4.3 million year over year, despite lower operating expenses, mainly reflecting a $4.8 million non-cash charge from revaluing financing tranche rights and lower other income. R&D expense fell 18%, largely because of lower spending on deprioritized izumerogant and external development costs for vidofludimus calcium and IMU-856. G&A expense rose 20%, principally due to personnel and stock-based compensation.
Cash increased from $46.7 million at December 31, 2023, primarily after $74.3 million of net proceeds from the January financing. Total assets were $104.2 million and total liabilities were $20.6 million at quarter-end. The filing reports no debt borrowings; lease liabilities were $1.1 million in present value. Stockholders’ equity was $83.6 million, and accumulated deficit was $440.5 million. Management expects existing cash to fund operations beyond twelve months from issuance of the financial statements.
Material developments and outlook
- Financing and dilution: The January 2024 private placement’s first tranche raised approximately $80 million gross. Two further $80 million tranches are conditional; the second depends on expected April 2025 progressive-MS trial data and specified stock-price and trading-volume tests. The third has similar conditions and may be funded on a cashless basis, reducing cash proceeds. The company issued common stock and pre-funded warrants, and shares outstanding rose from 45.2 million at year-end to 90.1 million at March 31.
- Pipeline timing: Vidofludimus calcium is in Phase 3 ENSURE trials for relapsing MS and a Phase 2 CALLIPER trial for progressive MS. CALLIPER topline data are expected around April 2025; ENSURE interim futility analysis is expected in late 2024 and the first trial readout in Q2 2026. IMU-856 is preparing for Phase 2 testing in active celiac disease; IMU-381 remains preclinical.
- Operating outlook and funding risk: Management expects significant expenses and increasing operating losses as development continues. Additional capital may be needed; future financing is not assured and could dilute shareholders or impose restrictive terms. A $250 million shelf registration filed in 2023 had not been declared effective as of May 8, 2024. ATM capacity remained, including $7.3 million under the December 2020 ATM and $80 million under the May 2022 ATM.
- Other notable items: Stockholders approved increasing authorized common shares to 500 million and repricing 3.3 million options; the repricing is expected to add $1.2 million of compensation expense over the remaining vesting period. A U.S. patent application covering a vidofludimus calcium polymorph received a notice of allowance, with expected protection into 2039 unless extended. The company disclosed no material litigation and no material change in internal control.
Key risks include clinical-trial delays or failures, regulatory uncertainty, dependence on external financing, potential shareholder dilution, and foreign-currency exposure. The filing estimates that a hypothetical 10% adverse currency move would reduce foreign subsidiaries’ net current assets by about $1.0 million and could affect quarterly net loss by about $1.9 million.
Important facts for investors to verify
- Whether the stated cash runway remains adequate as clinical spending and operating losses evolve.
- Progress and timing of CALLIPER, ENSURE, and the planned IMU-856 Phase 2 program, including whether trial milestones or readouts change.
- Whether the conditional second and third financing tranches’ clinical, share-price, and trading-volume conditions are met or waived, and the resulting cash proceeds and dilution.
- Availability and effectiveness of shelf and ATM registration capacity, and any additional capital needs or financing terms.
- Clinical-trial cost estimates, foreign-exchange exposure, and potential milestone or royalty obligations under the IMU-856 Daiichi Sankyo agreement.